Show simple item record

dc.contributor.authorJones, Ronald N.
dc.contributor.authorFritsche, Thomas R.
dc.contributor.authorSader, Helio S. [UNIFESP]
dc.date.accessioned2016-01-24T13:51:42Z
dc.date.available2016-01-24T13:51:42Z
dc.date.issued2008-10-01
dc.identifierhttp://dx.doi.org/10.1128/AAC.00294-08
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Washington: Amer Soc Microbiology, v. 52, n. 10, p. 3763-3775, 2008.
dc.identifier.issn0066-4804
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/30921
dc.description.abstractThe activity of DC-159a, a novel orally administered fluorinated quinolone, was evaluated by reference broth microdilution or agar dilution methods against 1,149 recently collected clinical isolates from five continents. Against pathogens associated with community-acquired respiratory tract infections (CA-RTIs), the MIC(90)s were 0.12 mu g/ml for Streptococcus pneumoniae, 0.015 to 0.03 mu g/ml for Haemophilus influenzae, 0.03 mu g/ml for Moraxella catarrhalis, and 0.12 mu g/ml for beta-hemolytic streptococci. Similarly, DC-59a was potent against various types of staphylococci (MIC90 range, 0.03 to 2 mu g/ml), Enterococcus faecalis (MIC90, 4 mu g/ml), wild-type isolates of the family Enterobacteriaceae (MIC90 range, 0.06 to 2 mu g/ml), wild-type Pseudomonas aeruginosa (MIC90, 2 mu g/ml), and Acinetobacter spp. (MIC90, 0.12 mu g/ml). Fluoroquinolone-nonsusceptible organism subsets usually had elevated DC-159a MICs, but the MICs were often two- to fourfold lower than those of levofloxacin and moxifloxacin. in conclusion, DC-159a appears to possess a balanced broad spectrum of activity that exceeds the activities of the currently marketed fluoroquinolones, especially against pathogens that cause CA-RTIs.en
dc.description.sponsorshipDaiichi Pharmaceutical Co., Ltd.
dc.format.extent3763-3775
dc.language.isoeng
dc.publisherAmer Soc Microbiology
dc.relation.ispartofAntimicrobial Agents and Chemotherapy
dc.rightsAcesso aberto
dc.titleAntimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolatesen
dc.typeArtigo
dc.contributor.institutionJMI Labs
dc.contributor.institutionTufts Univ
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.description.affiliationJMI Labs, N Liberty, IA 52317 USA
dc.description.affiliationTufts Univ, Sch Med, Boston, MA 02111 USA
dc.description.affiliationUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, São Paulo, Brazil
dc.identifier.fileWOS000259480800039.pdf
dc.identifier.doi10.1128/AAC.00294-08
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000259480800039


Files in this item

This item appears in the following Collection(s)

Show simple item record